CD28
细胞因子释放综合征
癌症研究
医学
免疫学
T细胞
嵌合抗原受体
免疫系统
生物
白细胞介素2
细胞因子
作者
Paul-Joseph P. Aspuria,Sandro Vivona,Michele Bauer,Marie Semana,Navneet P. Ratti,Scott McCauley,Romina M. Riener,René de Waal Malefyt,Deepti Rokkam,Jan Emmerich,Rob A. KASTELEIN,Patrick J. Lupardus,Martin Oft
标识
DOI:10.1126/scitranslmed.abg7565
摘要
) and effector T cells. In preclinical models of human CAR-refractory lymphoma, STK-009 treatment resulted in systemic and intratumoral expansion and activation of hoRb-expressing anti–CD19-CD28ζ CAR T cells (SYNCAR). The orthogonal IL-2 receptor/ligand system delivers complete responses in large subcutaneous lymphomas, even with substantially reduced CAR T cell doses, by selectively expanding and activating CAR T cells in vivo. STK-009 withdrawal allowed normal CAR T cell contraction, thereby limiting CRS induced by tumor antigen–specific T cell activation. These data suggest that the orthogonal IL-2 receptor/ligand system provides the in vivo control necessary to maximize efficacy of CAR T therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI